Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Japan Cabinet OKs FY2013 Budget, Social Security Outlays Nearly 29 Trillion Yen
January 30, 2013
- 13 Generic Makers Slapped with Improvement Order due to South Korean Supplier’s GMP Violation
January 30, 2013
- Membership of Committee on Non-Prescription Drugs to Be Evenly Split Between Medical, Pharmaceutical Communities
January 30, 2013
- Ordinary Diet Session Convenes; Bills to Amend Preventive Vaccination Law, Public Assistance Law Expected to Be Submitted
January 30, 2013
- Welfare Recipients Will Be Required to Use Generics from April 1; Those Who Request Original Drugs Will Be Asked to Give Reason
January 29, 2013
- Ministers of Health, Finance, and Internal Affairs Agree to Add 3 Vaccines to Public Vaccination Programs in April
January 29, 2013
- PAFSC First Committee on New Drugs to Discuss Approval of Japan’s First FD Treatment
January 28, 2013
- Preliminary Meetings of Regulatory Consultations Reach 331, Increase Found in Central and Peripheral Nervous System Drugs
January 25, 2013
- New Government Economic Panel Holds First Meeting, Takeda President Hasegawa Proposes to Bring Competition to Medical Industry
January 25, 2013
- Premium for New Drug Development to Be Discussed Alongside Long-Listed Drugs, Development of Drugs Used Off-Label: Health Minister Tamura
January 25, 2013
- Draft Basic Policy for FY2013 Budget Calls for “Prioritization” in Social Security to Minimize Increase in Public Burden
January 24, 2013
- MHLW Proposes Adding Test for Alcohol Consumption and Dependence to Health Checkup Program
January 24, 2013
- MOF’s Fiscal System Council Continues to Back Reference Price System, Price Cuts for Long-Listed Drugs
January 23, 2013
- LDP Group to Make New Rules on Online OTC Drug Sales in the Diet Session, Consider Lawmaker-Sponsored Bill
January 22, 2013
- PAFSC’s 2nd Committee to Discuss GSK’s CLL Treatment Arzerra on January 31
January 21, 2013
- MHLW Mulling Measure to Encourage Welfare Recipients to Use Generics
January 21, 2013
- How Will Party’s Return Affect Healthcare and Drug Policy? LDP Back in Power for First Time in 3 Years
January 17, 2013
- MHLW to Launch Panel by Jan.-End to Discuss New Rule for Online OTC Drug Sales after Top Court Ruling
January 16, 2013
- MHLW to Make HPV, Hib, and Pneumococcal Vaccines Mandatory, Excluding Them from the FY2012 Extra Budget
January 16, 2013
- At Request of JMA, Pharmacists to Be Required to Confirm that Buyers of Switch OTC Version of Epadel Had Medical Exam Before Purchase
January 15, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…